This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
CMC Strategy Forum Europe 2020
Share |
 

Thank all of you who attended to make CMC Strategy Forum Europe 2020 a success! We'll see you next year!

CASSS 2020 COVID-19 Action Plan

Updated April 1, 2020
Due to the current situation with the COVID-19 (also known as coronavirus) outbreak, this forum will now take place virtually 11-13 May 2020. To accommodate our global community, we made the decision to condense each session and keep the program length to three days. Each session will still include live speaker presentations and panel discussions. Each day will last approximately 3.5-4.5 hours with scheduled breaks. We are incredibly grateful for your support and flexibility during this difficult time.

Introduction
On behalf of the CMC Strategy Forum Global Steering Committee and CASSS, I would like to extend to you a warm welcome to the 14th meeting of the CMC Strategy Forum Europe that will be held 11-13 May 2020 in Stockholm, Sweden. 

The purpose of the CMC Strategy Forum Europe 2020 is to offer a blend of topics that characterize the challenges facing the biotechnology industry in the next decade. This Forum focuses on relevant CMC issues throughout the lifecycle of a product and thereby fosters collaborative technical and regulatory interactions. The Forum strives to share information with the regulatory agencies to assist them in merging good scientific and regulatory practices. The Forum will follow the established model of the CMC Forum series with focus on topics and regulatory updates relevant for Europe. The EFPIA MQEG Satellite Session will include concept paper updates on Polysorbates and Antibody Drug Conjugates, as well as a session on AAV: Current Status, Manufacutring Challenges and Opportunities.The technical sessions will be: Bioassay Capabilities and Applications for Therapeutic Monoclonal Antibodies; Applying Patient-centric Quality Standards Concepts to Biotechnology and Advanced Therapy Products; ICH Guideline Updates and Discussion: Q5A(R2), Q12, Q13 and Q2(R2)/Q14; and The Use of Next Generation Sequencing to Characterize and Detect Adventitious Viral Agents in Biological Products. 

With this exciting program, I would like to extend to you an invitation to attend and participate actively in making this Forum a great success.

Wassim Nashabeh
On behalf of the CMC Strategy Forum Global Steering Committee

 

 

 

 

Want more information? Check out the "More in this Section" dropdown box at the top of the page! 
Or contact CASSS at 510-428-0740 or casss@casss.org


 

 

more Calendar

9/14/2020 » 9/17/2020
Mass Spec 2020

9/28/2020 » 10/1/2020
CE Pharm 2020

Membership Software Powered by YourMembership  ::  Legal